Charles Schwab Investment Management Inc. Increases Holdings in ASP Isotopes Inc. (NASDAQ:ASPI)

Charles Schwab Investment Management Inc. raised its holdings in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 31.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 158,226 shares of the company’s stock after acquiring an additional 37,948 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.22% of ASP Isotopes worth $717,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the business. Hanson & Doremus Investment Management acquired a new position in ASP Isotopes in the fourth quarter valued at approximately $27,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of ASP Isotopes during the 3rd quarter worth approximately $42,000. SVB Wealth LLC acquired a new position in shares of ASP Isotopes in the 4th quarter valued at $49,000. Boston Financial Mangement LLC purchased a new position in shares of ASP Isotopes in the 4th quarter valued at $50,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in ASP Isotopes during the 3rd quarter worth $52,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Stock Performance

NASDAQ ASPI opened at $4.69 on Tuesday. The company has a fifty day moving average of $4.99 and a two-hundred day moving average of $4.95. The company has a market capitalization of $334.82 million, a PE ratio of -7.69 and a beta of 3.66. ASP Isotopes Inc. has a 1 year low of $1.86 and a 1 year high of $9.33. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.55 and a quick ratio of 7.54.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.